Immuneering Corporation (IMRX)
Immuneering Corporation
245 Main Street
Second Floor
Cambridge, MA 02142
United States
617 500 8080
https://immuneering.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 65
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Benjamin J. Zeskind M.B.A., Ph.D. | Co-Founder, President, CEO & Director | 935.09k | N/D | 1983 |
| Mr. Robert J. Carpenter M.B.A., M.S. | Co-Founder & Chair Emeritus | 75.36k | N/D | 1946 |
| Dr. Brett M. Hall Ph.D. | Chief Scientific Officer | 905.41k | N/D | 1969 |
| Mr. Harold E. Brakewood | Chief Business Officer | 579.77k | N/D | 1966 |
| Ms. Mallory Morales CPA | Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer | N/D | N/D | 1984 |
| Ms. Paula George CPA | Director of Accounting & Operations and Assistant Corporate Controller | N/D | N/D | N/D |
| Mr. Michael D. Bookman J.D. | Chief Legal Officer & Secretary | N/D | N/D | 1987 |
| Ms. Leah R. Neufeld | Chief People Officer | N/D | N/D | 1973 |
| Dr. Peter King Ph.D. | Head of Discovery & VP | N/D | N/D | N/D |
| Dr. Praveen Nair Ph.D. | Head of Translational Pharmacology & VP | N/D | N/D | N/D |
Descripción
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Immuneering Corporation a partir del 1 de mayo de 2024 es 7. Las puntuaciones principales son Auditoría: 7; Junta: 6; Derechos del accionista: 7; Compensación: 8.
